ATRC - AtriCure Inc Stock Price, Fair Value and News

23.16USD+0.53 (+2.34%)Market Closed

Market Summary

USD23.16+0.53

Market Closed

2.34%

ATRC Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

ATRC Stock Price

View Fullscreen

ATRC RSI Chart

ATRC Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-30.1

Price/Sales (Trailing)

2.7

EV/EBITDA

-55.57

Price/Free Cashflow

-45.32

ATRC Price/Sales (Trailing)

ATRC Profitability

Operating Margin

75.26%

EBT Margin

-8.81%

Return on Equity

-8.16%

Return on Assets

-6.29%

Free Cashflow Yield

-2.21%

ATRC Fundamentals

ATRC Revenue

Revenue (TTM)

414.6M

Rev. Growth (Yr)

16.43%

Rev. Growth (Qtr)

2.17%

ATRC Earnings

Earnings (TTM)

-37.2M

Earnings Growth (Yr)

-104.89%

Earnings Growth (Qtr)

-35.55%

Breaking Down ATRC Revenue

Last 7 days

2.9%

Last 30 days

-2.0%

Last 90 days

-30.8%

Trailing 12 Months

-53.5%

How does ATRC drawdown profile look like?

ATRC Financial Health

Current Ratio

Debt/Equity

0.14

Debt/Cashflow

-0.2

ATRC Investor Care

Shares Dilution (1Y)

2.41%

Diluted EPS (TTM)

-0.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	414.6M	0	0	0
2023	349.3M	365.7M	380.7M	399.2M
2022	289.6M	302.8M	315.6M	330.4M
2021	212.6M	243.1M	258.8M	274.3M
2020	230.1M	212.0M	210.1M	206.5M
2019	208.6M	215.7M	222.4M	230.8M
2018	180.4M	187.0M	194.8M	201.6M
2017	160.4M	166.0M	169.8M	174.7M
2016	135.8M	142.9M	149.8M	155.1M
2015	112.5M	118.6M	123.3M	129.8M
2014	87.3M	93.4M	99.9M	107.5M
2013	72.2M	74.4M	78.4M	81.9M
2012	66.2M	67.7M	68.6M	70.2M
2011	60.7M	63.3M	64.0M	64.4M
2010	0	56.0M	57.5M	59.0M
2009	0	0	0	54.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of AtriCure Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	noznesky justin j	sold	-36,135	24.09	-1,500	chief mktg & strategy officer
Apr 01, 2024	noznesky justin j	sold	-45,585	30.39	-1,500	chief mktg & strategy officer
Mar 18, 2024	dahlquist karl s.	sold	-60,621	32.16	-1,885	chief legal officer
Mar 14, 2024	carrel michael h	gifted	-	-	-2,000	president, ceo, & director
Mar 12, 2024	noznesky justin j	sold	-55,080	36.72	-1,500	chief mktg & strategy officer
Mar 05, 2024	dahlquist karl s.	sold	-307,510	37.36	-8,231	chief legal officer
Mar 01, 2024	yount deborah lee	sold (taxes)	-	-	-2,056	chief human resources officer
Mar 01, 2024	dahlquist karl s.	acquired	-	-	30,281	chief legal officer
Mar 01, 2024	seith douglas j	sold (taxes)	-529,543	36.28	-14,596	chief operating officer
Mar 01, 2024	noznesky justin j	acquired	-	-	28,622	chief mktg & strategy officer

Which funds bought or sold ATRC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-47.65	-1,423,580	1,146,960	-%
May 16, 2024	COMERICA BANK	added	70.52	23,922	76,712	-%
May 16, 2024	Grandeur Peak Global Advisors, LLC	added	49.01	2,231,790	10,495,800	0.83%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.05	-339,182	1,439,320	-%
May 16, 2024	Virtus Investment Advisers, Inc.	unchanged	-	-22,160	127,916	0.09%
May 16, 2024	Colony Group, LLC	new	-	321,000	321,000	-%
May 15, 2024	Squarepoint Ops LLC	reduced	-18.59	-1,749,890	3,966,010	0.01%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	added	220	818,849	1,292,460	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-18.46	-4,802,290	10,943,400	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	13.44	-419,964	12,271,400	-%

Are Funds Buying or Selling ATRC?

Are funds buying ATRC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATRC

No. of Funds

Unveiling AtriCure Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	alliancebernstein l.p.	7.2%	3,394,036	SC 13G/A
Feb 13, 2024	vanguard group inc	10.06%	4,766,029	SC 13G/A
Feb 01, 2024	invesco ltd.	2.5%	1,162,050	SC 13G/A
Jan 25, 2024	blackrock inc.	8.8%	4,193,887	SC 13G/A
Dec 08, 2023	vanguard group inc	10.01%	4,745,971	SC 13G/A
Feb 14, 2023	alliancebernstein l.p.	7.7%	3,565,726	SC 13G/A
Feb 14, 2023	alger associates inc	3.8%	1,755,398	SC 13G/A
Feb 09, 2023	vanguard group inc	9.44%	4,389,815	SC 13G/A
Feb 03, 2023	blackrock inc.	8.0%	3,735,766	SC 13G/A
Feb 03, 2023	invesco ltd.	7.2%	3,367,324	SC 13G/A

Recent SEC filings of AtriCure Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading

Peers (Alternatives to AtriCure Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-3.99%	-3.65%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	2.45%	-5.81%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-10.40%	-6.17%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-11.17%	-17.84%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.44%	23.99%	31.25	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	4.37%	-2.87%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	0.92%	-22.34%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-7.86%	-29.32%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.46%	29.28%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.82%	-4.37%	11.97	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	2.50%	-12.21%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-	-1.96%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-1.38%	-32.77%	-1.26	0.75	-3.19%	-337.41%
APYX	53.0M	50.5M	10.79%	-74.07%	-2.32	1.05	14.25%	-10.06%
AEMD	1.0M	3.7M	-72.22%	29.03%	-0.09	0.28	5.77%	8.23%

AtriCure Inc News

Latest updates

AtriCure Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	2.2%	108,851,000	106,543,000	98,290,000	100,918,000	93,494,000	88,028,000	83,246,000	84,529,000	74,576,000	73,218,000	70,460,000	71,376,000	59,275,000	57,725,000	54,757,000	40,824,000	53,225,000	61,321,000	56,614,000	58,906,000	53,966,000
Cost Of Revenue	3.2%	27,583,000	26,728,000	24,421,000	23,841,000	23,885,000	22,915,000	21,533,000	21,010,000	18,981,000	18,202,000	18,234,000	17,298,000	14,735,000	15,288,000	14,423,000	13,170,000	14,341,000	16,547,000	14,817,000	15,013,000	14,095,000
Gross Profit	1.8%	81,268,000	79,815,000	73,869,000	77,077,000	69,609,000	65,113,000	61,713,000	63,519,000	55,595,000	55,016,000	52,226,000	54,078,000	44,540,000	42,437,000	40,334,000	27,654,000	38,884,000	44,774,000	41,797,000	43,893,000	39,871,000
Operating Expenses	4.2%	92,185,000	88,483,000	81,958,000	81,221,000	75,391,000	69,249,000	72,436,000	77,179,000	69,745,000	67,518,000	-46,443,000	69,155,000	60,425,000	59,940,000	44,325,000	34,939,000	54,338,000	60,100,000	50,434,000	47,732,000	45,191,000
S&GA Expenses	6.9%	72,340,000	67,687,000	61,604,000	63,783,000	60,064,000	55,501,000	57,267,000	62,388,000	56,116,000	51,160,000	49,873,000	56,958,000	49,208,000	47,095,000	33,557,000	24,903,000	42,751,000	51,920,000	40,280,000	37,928,000	37,015,000
R&D Expenses	-4.6%	19,845,000	20,796,000	20,354,000	17,438,000	15,327,000	13,748,000	15,169,000	14,791,000	13,629,000	13,808,000	11,284,000	12,197,000	11,217,000	10,871,000	10,576,000	10,036,000	11,587,000	13,096,000	10,154,000	9,804,000	8,176,000
EBITDA Margin	-43.8%	-0.05	-0.03	-0.02	-0.03	-0.07	-0.10	-0.14	0.22	0.22	0.23	0.23	-0.18	-	-	-	-	-	-	-	-	-
Interest Expenses	-6.7%	1,677,000	1,798,000	1,772,000	1,719,000	1,636,000	1,561,000	1,324,000	1,101,000	1,000,000	1,083,000	1,449,000	1,197,000	1,189,000	1,194,000	1,232,000	1,231,000	1,228,000	1,257,000	1,113,000	879,000	862,000
Income Taxes	-50.9%	183,000	373,000	47,000	93,000	78,000	121,000	46,000	45,000	56,000	53,000	38,000	66,000	31,000	98,000	-4,000	12,000	8,000	48,000	75,000	10,000	66,000
Earnings Before Taxes	-39.0%	-13,086,000	-9,416,000	-9,008,000	-5,025,000	-6,398,000	-4,049,000	-12,226,000	-14,796,000	-15,127,000	-13,688,000	97,146,000	-16,185,000	-16,886,000	-18,464,000	-4,953,000	-8,224,000	-16,400,000	-16,048,000	-9,287,000	-4,091,000	-5,569,000
EBT Margin	-17.9%	-0.09	-0.07	-0.06	-0.08	-0.11	-0.14	-0.18	0.18	0.18	0.18	0.18	-0.23	-	-	-	-	-	-	-	-	-
Net Income	-35.6%	-13,269,000	-9,789,000	-9,055,000	-5,118,000	-6,476,000	-4,170,000	-12,272,000	-14,841,000	-15,183,000	-13,741,000	97,108,000	-16,251,000	-16,917,000	-18,562,000	-4,949,000	-8,236,000	-16,408,000	-16,096,000	-9,362,000	-4,101,000	-5,635,000
Net Income Margin	-17.8%	-0.09	-0.08	-0.07	-0.08	-0.11	-0.14	-0.18	0.18	0.18	0.18	0.18	-0.23	-	-	-	-	-	-	-	-	-
Free Cashflow	-2012.4%	-23,790,000	1,244,000	-2,108,000	-69,000	-6,581,000	-4,125,000	-6,929,000	45,000	-28,013,000	-2,409,000	-1,736,000	-8,746,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.6%	592	614	600	594	583	585	582	587	585	615	613	701	700	715	708	704	528	558	561	343	338
Current Assets	-7.9%	245	266	253	238	238	215	212	206	200	196	196	236	298	307	296	292	127	143	138	147	155
Cash Equivalents	-22.9%	65.00	84.00	81.00	67.00	77.00	58.00	49.00	55.00	28.00	44.00	40.00	68.00	85.00	42.00	33.00	89.00	22.00	28.00	33.00	25.00	21.00
Inventory	6.0%	72.00	68.00	62.00	55.00	49.00	46.00	44.00	41.00	41.00	39.00	39.00	38.00	36.00	35.00	34.00	33.00	32.00	29.00	28.00	24.00	24.00
Net PPE	-	-	-	-	-	-	-	39.00	36.00	33.00	31.00	30.00	30.00	28.00	28.00	29.00	30.00	32.00	33.00	31.00	28.00	27.00
Goodwill	0%	235	235	235	235	235	235	235	235	235	235	235	235	235	235	235	235	235	235	236	105	105
Liabilities	-8.4%	135	148	137	132	128	129	132	131	122	132	125	316	309	302	290	287	300	311	303	102	99.00
Current Liabilities	-17.9%	61.00	75.00	83.00	71.00	62.00	58.00	58.00	56.00	47.00	56.00	54.00	67.00	58.00	49.00	45.00	38.00	39.00	50.00	44.00	39.00	35.00
Long Term Debt	2.1%	62.00	61.00	42.00	47.00	52.00	57.00	60.00	60.00	60.00	60.00	56.00	44.00	49.00	53.00	50.00	54.00	58.00	60.00	60.00	34.00	33.00
LT Debt, Non Current	-100.0%	-	61.00	42.00	47.00	52.00	57.00	60.00	60.00	60.00	60.00	56.00	44.00	49.00	53.00	50.00	54.00	58.00	60.00	60.00	34.00	33.00
Shareholder's Equity	-2.1%	456	466	463	462	455	457	450	457	463	484	488	385	391	412	418	417	227	247	258	242	239
Retained Earnings	-3.7%	-370	-357	-347	-338	-333	-326	-322	-310	-295	-280	-266	-363	-347	-330	-311	-306	-298	-282	-266	-256	-252
Additional Paid-In Capital	0.4%	827	824	812	803	791	787	778	771	762	765	755	749	738	742	729	724	526	530	525	498	492
Shares Outstanding	1.8%	48.00	48.00	47.00	47.00	47.00	47.00	46.00	46.00	46.00	45.00	45.00	45.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,276	-	-	-	1,852	-	-	-	3,556	-	-	-	1,961	-	-	-	1,111	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-621.5%	-21,016	4,030	1,522	3,011	-4,079	46.00	-1,784	4,229	-24,632	301	-232	-4,533	-9,316	3,954	3,812	-11,548	-16,087	-3,529	-2,590	3,746	-13,438
Share Based Compensation	-0.5%	9,265	9,312	8,661	8,995	8,760	7,197	7,001	7,524	7,049	7,539	6,794	7,141	6,604	6,516	5,549	6,193	4,384	5,161	4,287	4,375	4,154
Cashflow From Investing	446.2%	9,644	-2,786	11,870	-16,080	28,813	7,002	-3,239	20,521	19,722	1,077	-25,101	-16,059	63,587	-1,980	-58,737	-112,812	17,331	-2,601	-9,633	-930	11,017
Cashflow From Financing	-433.3%	-7,862	2,359	132	2,994	-5,517	1,982	-405	1,861	-10,497	2,507	-2,260	2,818	-10,707	6,453	-301	191,074	-7,834	1,354	20,293	1,696	-8,970

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ATRC Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 108,851	$ 93,494
Cost of revenue	27,583	23,885
Gross profit	81,268	69,609
Operating expenses:
Research and development expenses	19,845	15,327
Selling, general and administrative expenses	72,340	60,064
Total operating expenses	92,185	75,391
Loss from operations	(10,917)	(5,782)
Other income (expense):
Interest expense	(1,677)	(1,636)
Interest income	952	875
Loss on debt extinguishment	(1,362)	0
Other income (expense)	(82)	145
Loss before income tax expense	(13,086)	(6,398)
Income tax expense	183	78
Net loss	$ (13,269)	$ (6,476)
Net (loss) income per share
Basic net loss per common share (in usd per share)	$ (0.28)	$ (0.14)
Diluted net loss per common share (in usd per share)	$ (0.28)	$ (0.14)
Weighted average shares outstanding
Weighted average shares outstanding—basic (in shares)	46,719	46,107
Weighted average shares outstanding—diluted (in shares)	46,719	46,107
Comprehensive income (loss):
Unrealized gain on investments	$ 539	$ 1,041
Foreign currency translation adjustment	(243)	(17)
Other comprehensive income	296	1,024
Net loss	(13,269)	(6,476)
Comprehensive loss, net of tax	$ (12,973)	$ (5,452)

ATRC Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 64,967	$ 84,310
Short-term investments	40,990	52,975
Accounts receivable, less allowance for credit losses of $350 and $500	55,319	52,501
Inventories	71,945	67,897
Prepaid and other current assets	12,004	8,563
Total current assets	245,225	266,246
Property and equipment, net	42,035	42,435
Operating lease right-of-use assets	4,199	4,324
Intangible assets, net	62,123	63,986
Goodwill	234,781	234,781
Other noncurrent assets	3,265	2,160
Total Assets	591,628	613,932
Current liabilities:
Accounts payable	28,991	27,354
Accrued liabilities	29,719	44,682
Current maturities of lease liabilities	2,542	2,533
Total current liabilities	61,252	74,569
Long-term debt	61,865	60,593
Finance and operating lease liabilities	10,956	11,368
Other noncurrent liabilities	1,242	1,234
Total Liabilities	135,315	147,764
Commitments and contingencies (Note 9)
Stockholders’ Equity:
Common stock, $0.000 par value, 90,000 shares authorized and 48,381 and 47,526 issued and outstanding	48	48
Additional paid-in capital	827,288	824,170
Accumulated other comprehensive loss	(697)	(993)
Accumulated deficit	(370,326)	(357,057)
Total Stockholders’ Equity	456,313	466,168
Total Liabilities and Stockholders’ Equity	$ 591,628	$ 613,932

About AtriCure Inc

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

CEO	Mr. Michael H. Carrel
WEBSITE	atricure.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1050

AtriCure Inc Frequently Asked Questions

What is the ticker symbol for AtriCure Inc? What does ATRC stand for in stocks?

ATRC is the stock ticker symbol of AtriCure Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AtriCure Inc (ATRC)?

As of Thu May 16 2024, market cap of AtriCure Inc is 1.09 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATRC stock?

You can check ATRC's fair value in chart for subscribers.

What is the fair value of ATRC stock?

You can check ATRC's fair value in chart for subscribers. The fair value of AtriCure Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AtriCure Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATRC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AtriCure Inc a good stock to buy?

The fair value guage provides a quick view whether ATRC is over valued or under valued. Whether AtriCure Inc is cheap or expensive depends on the assumptions which impact AtriCure Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATRC.

What is AtriCure Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, ATRC's PE ratio (Price to Earnings) is -29.41 and Price to Sales (PS) ratio is 2.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATRC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AtriCure Inc's stock?

In the past 10 years, AtriCure Inc has provided 0.037 (multiply by 100 for percentage) rate of return.